Hydroxyurea, blood transfusions, and hematopoietic stem cell transplantation represent the 3 disease-modifying therapies in children with sickle cell disease (SCD). Blood transfusions play an increasingly important role in both prevention and management of SCD complications in this age group. This review will focus on the indications of blood transfusion in children with SCD and modalities of its administration. It will also highlight the complications of this life-saving therapy and ways of optimizing transfusion to minimize its associated risks.
*Department of Pediatrics, Lebanese American University and University Medical Center Rizk Hospital, Beirut
†School of Medicine, Lebanese American University, Byblos, Lebanon
‡Department of Molecular and Cellular Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX
The authors declare no conflict of interest.
Reprints: Adlette Inati, MD, Department of Pediatrics, Lebanese American University and University Medical Center Rizk Hospital, P.O. Box 36, Byblos, Lebanon (e-mail: firstname.lastname@example.org).
Received September 20, 2015
Accepted June 22, 2016